- Home
- LIXT vs CXAI Comparison
LIXT vs CXAI Comparison
Compare LIXT & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- CXAI
- Stock Information
- Founded
- LIXT 2005
- CXAI N/A
- Country
- LIXT United States
- CXAI United States
- Employees
- LIXT N/A
- CXAI N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- CXAI EDP Services
- Sector
- LIXT Health Care
- CXAI Technology
- Exchange
- LIXT Nasdaq
- CXAI Nasdaq
- Market Cap
- LIXT 20.5M
- CXAI 17.8M
- IPO Year
- LIXT N/A
- CXAI N/A
- Fundamental
- Price
- LIXT $4.35
- CXAI $0.69
- Analyst Decision
- LIXT
- CXAI
- Analyst Count
- LIXT 0
- CXAI 0
- Target Price
- LIXT N/A
- CXAI N/A
- AVG Volume (30 Days)
- LIXT 129.2K
- CXAI 1.1M
- Earning Date
- LIXT 11-07-2025
- CXAI 11-12-2025
- Dividend Yield
- LIXT N/A
- CXAI N/A
- EPS Growth
- LIXT N/A
- CXAI N/A
- EPS
- LIXT N/A
- CXAI N/A
- Revenue
- LIXT N/A
- CXAI $6,005,000.00
- Revenue This Year
- LIXT N/A
- CXAI N/A
- Revenue Next Year
- LIXT N/A
- CXAI $60.00
- P/E Ratio
- LIXT N/A
- CXAI N/A
- Revenue Growth
- LIXT N/A
- CXAI N/A
- 52 Week Low
- LIXT $0.64
- CXAI $0.61
- 52 Week High
- LIXT $6.26
- CXAI $2.54
- Technical
- Relative Strength Index (RSI)
- LIXT 45.71
- CXAI 39.24
- Support Level
- LIXT $4.05
- CXAI $0.71
- Resistance Level
- LIXT $4.42
- CXAI $0.80
- Average True Range (ATR)
- LIXT 0.40
- CXAI 0.07
- MACD
- LIXT -0.04
- CXAI -0.01
- Stochastic Oscillator
- LIXT 41.51
- CXAI 0.04
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.